Drug Profile
Brigatinib - Takeda
Alternative Names: ALUNBRIG; AP-26113Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator ARIAD Pharmaceuticals
- Developer Takeda
- Class Antineoplastics; Diamines; Piperazines; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Cytochrome P-450 enzyme system stimulants; Epidermal growth factor receptor antagonists; ROS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- No development reported Lymphoma; Neuroblastoma
Most Recent Events
- 14 Feb 2024 Takeda completes a phase I bioavailability trial (In volunteers) in the US (PO) (NCT06132867)
- 17 Jan 2024 Takeda initiates a phase I bioavailability trial (In volunteers) in the US (PO) (NCT06132867)
- 13 Dec 2023 Efficacy data from a phase III ALTA-3 trial in Non small cell lung cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)